Haemonetics’ (HAE) “Buy” Rating Reaffirmed at BTIG Research

Haemonetics (NYSE:HAE)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research note issued on Friday,Benzinga reports. They currently have a $88.00 target price on the medical instruments supplier’s stock. BTIG Research’s price target points to a potential upside of 17.21% from the stock’s previous close.

Several other equities research analysts also recently commented on HAE. Weiss Ratings downgraded shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Needham & Company LLC raised their target price on Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Mizuho cut their price objective on Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Finally, Barrington Research raised their price objective on Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $79.70.

Haemonetics Price Performance

Shares of NYSE HAE opened at $75.08 on Friday. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $89.69. The company has a market cap of $3.51 billion, a PE ratio of 22.96, a P/E/G ratio of 0.91 and a beta of 0.43. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. The business has a 50-day simple moving average of $55.06 and a two-hundred day simple moving average of $62.80.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. Haemonetics’s revenue was down 5.3% on a year-over-year basis. During the same period last year, the firm posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts expect that Haemonetics will post 4.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Several institutional investors and hedge funds have recently modified their holdings of HAE. AQR Capital Management LLC boosted its stake in shares of Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after buying an additional 1,678,630 shares during the last quarter. Millennium Management LLC lifted its holdings in Haemonetics by 4,296.3% in the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after acquiring an additional 755,592 shares during the period. Norges Bank purchased a new stake in Haemonetics in the 2nd quarter worth approximately $36,822,000. Invenomic Capital Management LP boosted its position in Haemonetics by 1,691.5% in the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock worth $24,288,000 after purchasing an additional 470,502 shares in the last quarter. Finally, SG Capital Management LLC grew its stake in shares of Haemonetics by 92.5% during the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after purchasing an additional 435,660 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.